RELATIONSHIP OF THE POLYMORPHIC VARIANT RS989692 OF THE NEPRILYSIN GENE (MME) WITH THE LEVELS OF NATRIURETIC PEPTIDES AND ITS CLINICAL SIGNIFICANCE IN PATIENTS WITH HEART FAILURE AND ATRIAL FIBRILLATION
Abstract
Background. The variability in the activity of natriuretic peptides (NUPs) is determined genetically, as evidenced by the association of polymorphic variants encoding brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) with an increased risk of cardiovascular (CV) disease. The aim of the study. To determine the frequency of alleles and genotypes of the SNP rs989692 of the neprilysin gene (MME). To determine the association of SNP rs989692 in MME with the concentration of NUP and soluble neprilysin and to evaluate its prognostic value in relation to the development of adverse cardiovascular events in patients with heart failure (HF) associated with a left ventricular ejection fraction (LVEF) <50% and persistent or long-term persistent atrial fibrillation (AF). Material and methods. The main group included 152 patients with HF, the control group included 35 individuals without CV disease. The levels of ANP, BNP, NT-proBNP and soluble neprilysin were determined for all patients. The genetic study of the SNP rs989692 in the MME gene was carried out by polymerase chain reaction. The endpoint: hospitalization due to HF progression. The composite endpoint: hospitalization due to HF progression, new onset or progressive exertional angina pectoris, myocardial infarction. Results. The frequency distribution of genotypes and alleles of the SNP rs989692 in MME did not differ significantly between the control and experimental groups. The levels of ANP, BNP and neprilysin in patients with HF in combination with AF did not differ depending on the SNP rs989692 in MME genotype. Patients with HF associated with LVEF <50%, AF and TT genotype rs989692 in MME had higher levels of NT-proBNP (those with CC genotype – 964 [655.1; 1724] pg/ml, those with TC genotype – 1074.1 [857; 1944] pg/ml, those with the TT genotype – 2992 [886; 4885] pg/ml, p<0.05). The presence of the homozygous TT genotype in patients with HF combined with LVEF <50% and AF was associated with an increased risk of developing adverse CV events, OR=1.9 [95% CI from 1.2 to 3.09]. Conclusion. Patients with HF associated with LVEF <50% in combination with permanent or long-term persistent AF with homozygous TT genotype rs989692 of the MME gene have higher levels of NT-proBNP and a higher risk of developing adverse cardiovascular events.
References
Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications. Pharmacol Ther. 2021;227:107863. https://doi.org/10.1016/j.pharmthera.2021.107863.
Man J, Barnett P, Christoffels VM. Structure and function of the Nppa-Nppb cluster locus during heart development and disease. Cell Mol Life Sci. 2018;75(8):1435-1444. https://doi.org/10.1007/s00018-017-2737-0.
Newton-Cheh C, Larson MG, Vasan RS, Levy D, Bloch KD, Surti A, Guiducci C, Kathiresan S, Benjamin EJ, Struck J, Morgenthaler NG, Bergmann A, Blankenberg S, Kee F, Nilsson P, Yin X, Peltonen L, Vartiainen E, Salomaa V, Hirschhorn JN, Melander O, Wang TJ. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348-53. https://doi.org/10.1038/ng.328.
Maisel AS, Duran JM, Wettersten N. Natriuretic Peptides in Heart Failure: Atrial and B-type Natriuretic Peptides. Heart Fail Clin. 2018;14(1):13-25. https://doi.org/10.1016/j.hfc.2017.08.002.
Lanfear DE, Chow S, Padhukasahasram B, Li J, Langholz D, Tang WH, Williams LK, Sabbah HN. Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail. 2014;20(9):662-8. https://doi.org/10.1016/j.cardfail.2014.06.357.
Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992;38(9):1785-91.
Emrich IE, Vodovar N, Feuer L, Untersteller K, Nougue H, Seiler-Mussler S, Fliser D, Launay JM, Heine GH. Do plasma neprilysin activity and plasma neprilysin concentration predict cardiac events in chronic kidney disease patients? Nephrol Dial Transplant. 2019;34(1):100-108. https://doi.org/10.1093/ndt/gfy066.
Standeven KF, Hess K, Carter AM, Rice GI, Cordell PA, Balmforth AJ, Lu B, Scott DJ, Turner AJ, Hooper NM, Grant PJ. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35(8):1031-40. https://doi.org/10.1038/ijo.2010.227.
Miners JS, Barua N, Kehoe PG, Gill S, Love S. Aβ- degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol. 2011;70(11):944-59. https://doi.org/10.1097/NEN.0b013e3182345e46.
Simonini G, Azzari C, Gelli AM, Giani T, Calabri GB, Leoncini G, Del Rosso A, Generini S, Cimaz R, Cerinic MM, Falcini F. Neprilysin levels in plasma and synovial fluid of juvenile idiopathic arthritis patients. Rheumatol Int. 2005;25(5):336-40. https://doi.org/10.1007/s00296-004-0447-z.
Bayés-Genís A, Barallat J, Pascual-Figal D, Nuñez J, Miñana G, Sánchez-Mas J, Galan A, Sanchis J, Zamora E, Pérez-Martínez MT, Lupón J. Prognostic Value and Kinetics of Soluble Neprilysin in Acute Heart Failure: A Pilot Study. JACC Heart Fail. 2015;3(8):641-4. https://doi.org/10.1016/j.jchf.2015.03.006.
Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65(7):657-65. https://doi.org/10.1016/j.jacc.2014.11.048.
Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail. 2016;18(1):89-93. https://doi.org/10.1002/ejhf.435.
General Assembly of the World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81(3):14-8.
Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, Wieben ED, Yee VC, Weinshilboum RM. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010;49(5):864-74. https://doi.org/10.1016/j.yjmcc.2010.07.020.
Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Rev. 2010;15(3):219-28. https://doi.org/10.1007/s10741-008-9113-y.
Cannone V, Cefalu’ AB, Noto D, Scott CG, Bailey KR, Cavera G, Pagano M, Sapienza M, Averna MR, Burnett JC Jr. The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. Diabetes Care. 2013;36(9):2850-6. https://doi.org/10.2337/dc12-2337.
Lanfear DE, Sunkara B, Li J, Rastogi S, Gupta RC, Padhukasahasram B, Williams LK, Sabbah HN. Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res. 2013;6(5):826-33. https://doi.org/10.1007/s12265-013-9491-y.
Miura S, Nakayama A, Tomita S, Matsuo Y, Suematsu Y, Saku K. Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide. Clin Exp Hypertens. 2015;37(5):353-7. https://doi.org/10.3109/10641963.2014.987391.
von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail. 2015;8(1):71-8. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001785.
Bayés-Genís A, Barallat J, Galán A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupón J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65(7):657-65. https://doi.org/10.1016/j.jacc.2014.11.048.
Kuruppu S, Rajapakse NW, Minond D, Smith AI. Production of soluble Neprilysin by endothelial cells. Biochem Biophys Res Commun. 2014;446(2):423-7. https://doi.org/10.1016/j.bbrc.2014.01.158.
Matsiukevich M, Snezhitskiy V. Metalloproteinase (neprilysin) and natriuretic peptides: relationship of metabolic effects and clinical significance in patients with heart failure and atrial fibrillation. Laboratory diagnostics. Eastern Europe. 2022;11:(4):482-496. https://doi.org/10.34883/PI.2022.11.4.008. https://elibrary.ru/nlnxyi.
